Journal of Clinical Psychiatry

Subject Index to Volume 52: January 1991 Through December 1991

Academic Highlights
Current status of tricyclic antidepressants in psychiatry: their pharmacology and clinical applications. Apr 193–200
Depression: patient profile and treatment options—confront issues with the experts. Oct 437–445
Evolving standards of antidepressant therapy. Sept 391–397
Acute Intermittent Porphyria
Fluoxetine treatment of depressive symptoms in acute intermittent porphyria [letter]. Vaz, Mar 138
Adolescents
Paranoid schizophrenia in adolescence. Apter, Sept 365–368
Affective Disorders
Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. Kupfer, Feb suppl 12–16
Serotonin and behavior: emphasis on motor control. Jacobs, Dec suppl 17–23
Aggression see Violence
Akathisia
Placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. Wells, June 255–260
Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. Rothschild, Dec 491–493
Alexithymia
Alexithymia and posttraumatic stress disorder [letter]. Alvarez; Hyer reply, July 317–319
Alprazolam
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. Tesar, Feb 69–76
Open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. Tollefson, Dec 502–508
Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Deltito, Mar 121–127
Alzheimer's Disease
Experiences with depression in a dementia clinic. Weiner, May 234–238
Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush, July 300–303
Neuroanatomical correlates of clinical misidentification and misperception in senile dementia of the Alzheimer type. Förstl, June 268–271
Use of selegiline in Alzheimer's patients with behavior problems. Goad, Aug 342–345
Amitriptyline
Effects of placebo washout and dose in a comparison of sertraline and amitriptyline [letter]. Karagianis; Reimherr reply, Sept 386
Anemia
Changing psychiatric symptoms in a patient with vitamin B_{12} deficiency [letter]. Verbanck, Apr 182–183
Anorexia Nervosa
Fluoxetine in anorexia nervosa [letter]. Lee; Gwirtsman reply, May 240–241
Open trial of fluoxetine in patients with anorexia nervosa. Kaye, Nov 464–471
Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood. Kaye, Dec suppl 41–48
Antidepressants, Tricyclic
Current status of tricyclic antidepressants in psychiatry: their pharmacology and clinical applications. Apr Academic Highlights 193–200
Is doxepin a safer tricyclic for the heart? Roose, Aug 338–341
Painful ejaculation associated with antidepressants in four patients. Aizenberg, Nov 461–463
Panic disorder: a treatment update. Burrows, July suppl 24–26
Antidepressive Agents
Antidepressant adverse drug reactions. Nierenberg, June suppl 40–47
Antidepressant treatment and side effect considerations. Tollefson, May suppl 4–13
Behavioral studies of serotonin receptor agonists as antidepressant drugs. Lucki, Dec suppl 24–31
Bright light augmentation in antidepressant nonresponders. Levitt, Aug 336–337
Dosing strategies for antidepressant agents. Schatzberg, May suppl 14–20
Evolving standards of antidepressant therapy. Sept Academic Highlights 391–397
Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. Kafka, Feb 60–65
Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Preskorn, June suppl 23–33
Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists. Nierenberg, Sept 383–385
Anxiety
Anxiety disorders during acute bereavement [letter]. Friedman; Jacobs reply, May 241
Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. Ratey, Apr 159–162
Coexisting depression and anxiety: special diagnostic and treatment issues. Lydiard, June suppl 48–54
Introduction. Anxiety and insomnia: current trends in research and therapeutics. Hishikawa, July suppl 3–4
Lifetime history of panic attacks and epilepsy: an association from a general population survey [letter]. Pariente, Feb 88–89
Open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. Tollefson, Dec 502–508
Overview of anxiety disorders: prevalence, biology, course, and treatment. Schatzberg, July suppl 5–9
Summary. Anxiety and insomnia: current trends in research and therapeutics. Hishikawa, July suppl 27
Behavior
Use of selegiline in Alzheimer's patients with behavior problems. Goad, Aug 342–345
Benzodiazepines
Appropriate use of benzodiazepines in insomnia: clinical update. Hishikawa, July suppl 10–13
Benzodiazepine hypnotics: sorting the pharmacokinetic facts. Greenblatt, Sept suppl 4–10
Criteria for selection of appropriate benzodiazepine hypnotic therapy. Mendels, Sept suppl 42–46
Determinants of pharmacologic effects and toxicity of benzodiazepine hypnotics: role of lipophilicity and plasma elimination rates. Arnold, Sept suppl 11–14
Introduction. Benzodiazepine hypnotics: the interface of basic and clinical science. Greenblatt, Sept suppl 3
Introduction. Overview of the efficacy and safety of benzodiazepine hypnotics using objective methods. Dement, Sept suppl 27–30
Panic disorder: a treatment update. Burrows, July suppl 24–26
Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. Wamsley, Sept suppl 15–20
Residual effects of hypnotics: an update. Hindmarch, July suppl 14–15
Review of the safety profiles of benzodiazepine hypnotics. Roth, Sept suppl 38–41
Bipolar Disorder
Bipolar disorder in prepubertal children in a special educational setting: is it rare? Isaac, Apr 165–168
Blockers, Adrenergic
Labetalol and ECT [letter]. Silver; Knos reply, Sept 387–388
Placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. Wells, June 255–260
Blood Levels
Therapeutic drug monitoring for antidepressants:

efficacy, safety, and cost effectiveness. Preskorn, June suppl 23–33

Blood Pressure

Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. Keck Jr, June 250–254

ECT response and blood pressure reduction [letter]. Masiar; Swartz reply, Apr 183

Books Reviewed

Asaad G: *Hallucinations in Clinical Psychiatry: A Guide for Mental Health Professionals*. Gold Jr, Nov 482

Barkley RA (ed): *Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*. Soltys, Oct 436

Bergmann MS, Hartman FR (eds): *The Evolution of Psychoanalytic Technique*. St. John, June 283–284

Blanchard R, Steiner BW (eds): *Clinical Management of Gender Identity Disorders in Children and Adults*. Levine, June 283

Bloomingdale LM, Swanson J (eds): *Attention Deficit Disorder*. Huessy, Feb 92

Cohen NL (ed): *Psychiatry Takes to the Streets: Outreach and Crisis Intervention for the Mentally Ill*. Scott, Aug 354–355

Committee on Medical Education of the Group for the Advancement of Psychiatry: *A Casebook in Psychiatric Ethics*. Walker, May 243

Committee on the College Student of the Group for the Advancement of Psychiatry: *Psychotherapy With College Students*. Cowie, Nov 481–482

Easson WM, Rock NL: *Psychiatry Specialty Board Review*. Billings, Aug 355

Eiser C: *Chronic Childhood Disease: An Introduction to Psychological Theory and Research*. Kontras, July 320

Esman AH (ed): *Essential Papers on Transference*. St. John, Sept 389

Etezady MH (ed): *The Neurotic Child and Adolescent*. Mumtaz, May 243–244

Everett CA (ed): *Children of Divorce: Developmental and Clinical Issues*. Surawicz, July 320–321

Feigelman W: *Treating Teenage Drug Abuse in a Day Care Setting*. King, Jan 47

Fleischman PR: *The Healing Spirit: Explorations in Religion and Psychotherapy*. Rice, Aug 355

Fogel BS, Furino A, Gottlieb GL (eds): *Mental Health Policy for Older Americans: Protecting Minds at Risk*. Surawicz, Feb 91–92

Frances RJ, Miller SI (eds): *Clinical Textbook of Addictive Disorders*. Strassman, Oct 435

Franks CM, Wilson GT, Kendall PC, Foreyt JP: *Review of Behavior Therapy: Theory and Practice, vol. 12*. Rosenthal, May 242–243

Fromm E, Kahn S: *Self-Hypnosis: The Chicago Paradigm*. Battle, Mar 142–143

Goldstein S, Goldstein M: *Managing Attention Disorders in Children*. Dennett, Mar 143

Hale MS, Basel MD (eds): *Methods in Teaching Consultation-Liaison Psychiatry*. Hill, Apr 191

Hale MS, Basel MD, Hillard JR (eds): *Manual of Clinical Emergency Psychiatry*. Gold Jr, Jan 45–46

Hall P, Brockington IF (eds): *The Closure of Mental Hospitals*. Gold Jr, Dec 517

Hauser P (ed): *Brain Imaging in Affective Disorders*. Nasrallah, Dec 516

Hillard JR (ed): *Manual of Clinical Emergency Psychiatry*. Gold Jr, Jan 45–46

Hollander MH, Ford CV: *Dynamic Psychotherapy: An Introductory Approach*. Deltito and Panarites, Apr 192

Isaac RJ, Armat VC: *Madness in the Streets: How Psychiatry and the Law Abandoned the Mentally Ill*. Gold Jr, Apr 190

Jaffe SL: *Adolescent Chemical Dependency Recovery*. King, Mar 142

Johnson AB: *Out of Bedlam: The Truth About Deinstitutionalization*. North, Apr 189

Kammerer WS, Gross RJ (eds): *Medical Consultation: The Internist on Surgical, Obstetric, and Psychiatric Services*. Wise, Sept 389

Kates N, Greiff BS, Hagen DQ: *The Psychosocial Impact of Job Loss*. Tanay, Jan 45

Kaufman E: *Help at Last: A Complete Guide to Coping With Chemically Dependent Men*. King, Oct 435

Kennerley H: *Managing Anxiety: A Training Manual*. Côté and Barlow, June 284

Lewis M, Volkmar F: *Clinical Aspects of Child and Adolescent Development, 3rd ed*. Kerr, May 244

Lindsay J, MacDonald A, Starke I: *Delirium in the Elderly*. Schuster, Dec 517

Luborsky L, Crits-Christoph P: *Understanding Transference: The Core Conflictual Relationship Theme Method*. Kuhne, Mar 141–142

Manning DW, Francis AJ (eds): *Combined Pharmacotherapy and Psychotherapy for Depression*. Beitman, Nov 481

Maser JD, Cloninger CR (eds): *Comorbidity of Mood and Anxiety Disorders*. Alarcon, Feb 91

McCully RS: *The Enigma of Symbols in Fairy Tales*. Hart, Dec 516–517

Menkes JH: *Textbook of Child Neurology, 4th ed*. Pataki, Nov 483

Nathanson DL (ed): *The Many Faces of Shame*. Hart, July 321

Nemiroff RA, Colarusso CA (eds): *New Dimensions in Adult Development*. Hughes, Apr 191

Notman MT, Nadelson CC (eds): *Women and Men: New Perspectives on Gender Differences*. Surawicz, Dec 516

Osgood NJ, Brant BA, Lipman A (eds): *Suicide Among the Elderly in Long-Term Care Facilities*. Heiman, Oct 435–436

Plakun EM: *New Perspectives on Narcissism*. Links, Apr 189–190

Sandler M, Collins GM (eds): *Migraine: A Spectrum of Ideas*. Wise, Mar 141

Shapiro D: *Psychotherapy of Neurotic Character*. Yeomans, Jan 46

Skodol AE: *Problems in Differential Diagnosis: From DSM-III to DSM-III-R in Clinical Practice*. Billings, Jan 46–47

Stark KD; Elliott SN, Witt JC (eds): *Childhood Depression: School-Based Intervention*. Henigan, July 320

Stotland NL (ed): *Psychiatric Aspects of Reproductive Technologies*. Levine, Sept 390

Stotland NL, Garrick TR: *Manual of Psychiatric Consultation*. Hill, Mar 143

Woodside DB, Shekter-Wolfson L (eds): *Family Approaches in Treatment of Eating Disorders*. Larocca, Oct 436

Yapko MD: *Trancework: An Introduction to the Practice of Clinical Hypnosis*. Battle, Nov 482–483

Young RA, Borgen WA (eds): *Methodological Approaches to the Study of Career*. Tanay, May 242

Zal HM: *Panic Disorder: The Great Pretender*. Raj, May 242

Brain

Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. Azmitia, Dec suppl 4–16

Brain abnormalities in schizophrenia [letter]. Friedman; Joseph reply, Jan 43

Clomipramine treatment of trichotillomania [letter]. Friedman, Nov 478–479

Fluoxetine-induced bradycardia [letter]. Friedman; Buff reply, Nov 477

Fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. Hoehn-Saric, Mar 131–133

Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. Hernandez, Dec suppl 32–40

Bromocriptine

Bromocriptine and neuroleptic malignant syndrome [letter]. Rosebush, Jan 41–42

Pergolide mesylate treatment of cocaine withdrawal. Malcolm, Jan 39–40

Bulimia

Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Goldbloom, June 261–262

Comorbidity and medical complications of bulimia nervosa. Mitchell, Oct suppl 13–20

Course and outcome of bulimia nervosa. Herzog, Oct suppl 4–8

Introduction. Recent advances in bulimia nervosa. Herzog, Oct suppl 3

Neurochemistry of bulimia nervosa. Kaye, Oct suppl 21–28

Nonpharmacologic treatments of bulimia nervosa. Agras, Oct suppl 29–33

Outcome and clinical course in inpatient bulimic women: a 2- to 9-year follow-up study. Fallon, June 272–278

Psychopharmacologic treatment of bulimia nervosa. Walsh, Oct suppl 34–38

Questions and answers. Recent advances in bulimia nervosa. Oct suppl 39–43

Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood. Kaye, Dec suppl 41–48

Bupropion

Double-blind comparison of bupropion and fluoxetine in depressed outpatients. Feighner, Aug 329–335

Menstrual irregularities associated with bupropion treatment. Halbreich, Jan 15–16

102-center prospective study of seizure in association with bupropion. Johnston, Nov 450–456

Tinnitus related to bupropion treatment [letter]. Settle Jr, Aug 352

Buspirone

Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. Jenike, Jan 13–14

Buspirone in major depression: a controlled study. Rickels, Jan 34–38

Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. Ratey, Apr 159–162

Possible augmentation of antidepressant response by buspirone. Jacobsen, May 217–220

Cannabis

Case of mania as a result of fluoxetine-marijuana interaction [letter]. Stoll, June 280–281

Capgras Syndrome

Neuroanatomical correlates of clinical misidentification and misperception in senile dementia of

the Alzheimer type. Förstl, June 268–271
Carbamazepine
Carbamazepine for treatment-resistant melancholia. Cullen, Nov 472–476
Thrombocytopenia associated with carbamazepine: a case series. Tohen, Dec 496–498
Cardiac Side Effects
Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. Keck Jr, June 250–254
Bradycardia and syncope induced by fluoxetine [letter]. Feder; Ellison reply, Mar 139
Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. Buff, Apr 174–176
Is doxepin a safer tricyclic for the heart? Roose, Aug 338–341
Labetalol and ECT [letter]. Kellner; Knos reply, Sept 386–388
Labetalol and ECT [letter]. Silver; Knos reply, Sept 387–388
Role of the right hemisphere in fluoxetine-induced bradycardia and syncope [letter]. Friedman, Mar 138–139
Unexpected deaths in depressed medical inpatients treated with fluoxetine. Spier, Sept 377–382
Cardiovascular Diseases
Death, depression, and heart disease. Roose, June suppl 34–39
Is doxepin a safer tricyclic for the heart? Roose, Aug 338–341
Catatonia
Lorazepam and catatonia [letter]. Menza; Rosebush reply, Apr 186–188
Thromboembolism complicating psychiatric stupor [letter]. O'Brien, Mar 137–138
Catecholamines
ECT response and blood pressure reduction [letter]. Masiar; Swartz reply, Apr 183
Cerebrovascular Disorders
Cerebral infarct presenting as mania [letter]. Fawcett, Aug 352–353
Children
Behavioral inhibition in children: a possible precursor to panic disorder or social phobia. Rosenbaum, Nov suppl 5–9
Bipolar disorder in prepubertal children in a special educational setting: is it rare? Isaac, Apr 165–168
P.R.N. medications in child psychiatric patients: a pilot placebo-controlled study. Vitiello, Dec 499–501
Chronic Fatigue Syndrome see Fatigue
Cimetidine
Case report of cimetidine-induced clozapine toxicity. Szymanski, Jan 21–22
Clobazam
Clobazam and panic disorder [letter]. Name Withheld Upon Request, Jan 44
Clomipramine
Clomipramine in obsessive compulsive disorder [letter]. Lee; Greist reply, Apr 183–185
Clomipramine treatment of trichotillomania [letter]. Friedman, Nov 478–479
Clomipramine treatment of trichotillomania: a follow-up report on four cases. Pollard, Mar 128–130
Painful ejaculation associated with antidepressants in four patients. Aizenberg, Nov 461–463
Potential antidopaminergic effects of serotonin reuptake inhibitors [letter]. Kim, Jan 42
Serotonin, suicide, and aggression: clinical studies. Golden, Dec suppl 61–69
Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. O'Sullivan, Apr 150–155
Clonazepam
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. Tesar, Feb 69–76
Long-term treatment of social phobia with clonazepam. Davidson, Nov suppl 16–20
Clozapine
Case of clozapine-induced neuroleptic malignant syndrome. Miller, Mar 99–101
Case report of cimetidine-induced clozapine toxicity. Szymanski, Jan 21–22
Clozapine and jaw dyskinesia: a case report. de Leon, Dec 494–495
Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. McElroy, Oct 411–414
Clozapine-induced neuroleptic malignant syndrome. DasGupta, Mar 105–107
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. Alphs, Aug 346–348
Effect of phenytoin on plasma clozapine concentrations in two patients. Miller, Jan 23–25
Neuroleptic malignant syndrome associated with clozapine use. Anderson, Mar 102–104
Cocaine
Cocaine-induced psychosis. Brady, Dec 509–512
Fluoxetine treatment of cocaine abuse in heroin addicts. Pollack, Jan 31–33
Pergolide mesylate treatment of cocaine withdrawal. Malcolm, Jan 39–40
Prolonged cocaine psychosis implies underlying major psychopathology [letter]. Satel, Aug 349–350
Comorbidity
Coexisting depression and anxiety: special diagnostic and treatment issues. Lydiard, June suppl 48–54
Comorbidity and medical complications of bulimia nervosa. Mitchell, Oct suppl 13–20
Continuation Treatment
Long-term treatment of social phobia with clonazepam. Davidson, Nov suppl 16–20
Corrections
Anxiety and adjustment disorder: a treatment approach. Schatzberg, 1990 Nov suppl 20–24; Correction, Mar 140
Biological basis of depression and therapeutic relevance. Richelson, June suppl 4–10; Correction, Aug 353
Rapid treatment of depression with selegiline-phenylalanine combination [letter]. Sabelli, Mar 137; Correction, May 241
Summary. The clinician's challenge: strategies for treatment of depression in the 1990s. Gelenberg, June suppl 68–69; Correction, July 319
Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Preskorn, June suppl 23–33; Correction, Aug 353
Cortisol
Levels of urinary free cortisol in social phobia. Potts, Nov suppl 41–42
Crying
Is the tendency to weep one of the most useful indicators for depressed mood [letter]? Okada, Aug 351–352
Cyproheptadine
Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Goldbloom, June 261–262
Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. Feder, Apr 163–164
De Clérambault's Syndrome
De Clérambault's syndrome in sexually experienced women. Giannini, Feb 84–86
Delusional Disorder
Pimozide in clinical psychiatry [letter]. Phillips; Opler reply, Dec 514–515
Dementia
Experiences with depression in a dementia clinic. Weiner, May 234–238
Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush, July 300–303
Neuroanatomical correlates of clinical misidentification and misperception in senile dementia of the Alzheimer type. Förstl, June 268–271
Depression see also Seasonal Affective Disorder
Acute open-trial nortriptyline therapy of bereavement-related depression in late life. Pasternak, July 307–310
Augmentation regimens for depression. Nemeroff, May suppl 21–27
Beyond serotonin. Meltzer, May Suppl 58–62
Biological basis of depression and therapeutic relevance. Richelson, June suppl 4–10
Bright light augmentation in antidepressant nonresponders. Levitt, Aug 336–337
Buspirone in major depression: a controlled study. Rickels, Jan 34–38
Carbamazepine for treatment-resistant melancholia. Cullen, Nov 472–476
Changing horizon in the treatment of depression: scientific/clinical publication overview. Stokes, May suppl 35–43
Changing psychiatric symptoms in a patient with vitamin B_{12} deficiency [letter]. Verbanck, Apr 182–183
Closing remarks. The changing horizon in the treatment of depression and related disorders. Rosenbaum, May suppl 63–64
Coexisting depression and anxiety: special diagnostic and treatment issues. Lydiard, June suppl 48–54
Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. Fabre, June suppl 62–67
Death, depression, and heart disease. Roose, June suppl 34–39
Depression: challenges for the future. Dunner, May suppl 44–51
Depression: patient profile and treatment options—confront issues with the experts. Oct Academic Highlights 437–445
Dexamethasone for the treatment of depression: a preliminary report. Arana. July 304–306
Diagnosis and treatment of insomnia and depression. Ware, June suppl 55–61
Double-blind comparison of bupropion and fluoxetine in depressed outpatients. Feighner, Aug 329–335
Effects of placebo washout and dose in a comparison of sertraline and amitriptyline [letter]. Karagianis; Reimherr reply, Sept 386
Experiences with depression in a dementia clinic. Weiner, May 234–238
Fluoxetine treatment of depressive symptoms in acute intermittent porphyria [letter]. Vaz, Mar 138

Fluoxetine versus trazodone: efficacy and activating-sedating effects. Beasley Jr, July 294–299
Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. Hernandez, Dec suppl 32–40
Introduction. The changing horizon in the treatment of depression and related disorders. Rosenbaum, May suppl 3
Introduction. The clinician's challenge: strategies for treatment of depression in the 1990s. Gelenberg, June suppl 3
Is the tendency to weep one of the most useful indicators for depressed mood [letter]? Okada, Aug 351–352
Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. Kupfer DJ, Feb suppl 12–16
Long-term follow-up of chronic depression treated with imipramine. Kocsis, Feb 56–59
Long-term treatment of depression. Kupfer, May suppl 28–34
Methylphenidate in depressed medically ill patients. Rosenberg, June 263–267
Obsessive compulsive disorder, depression, and fluoxetine. Hollander, Oct 418–422
Overview of chronic fatigue syndrome. Krupp, Oct 403–410
Possible augmentation of antidepressant response by buspirone. Jacobsen, May 217–220
Prophylactic efficacy of maprotiline on unipolar depression relapse. Rouillon, Oct 423–431
Rapid treatment of depression with selegiline-phenylalanine combination [letter]. Sabelli, Mar 137; Correction, May 241
Recognition and treatment of depression in the elderly. Small, June suppl 11–22
Role of serotonin in therapy of depression and related disorders. Fuller, May suppl 52–57
Speech pauses and diagnosis [letter]. Friedman, Apr 181–182
Summary. The clinician's challenge: strategies for treatment of depression in the 1990s. Gelenberg, June suppl 68–69; Correction, July 319
Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists. Nierenberg, Sept 383–385

Desipramine
Raised serum levels of desipramine with the antiarrhythmic propafenone [letter]. Katz, Oct 432–433

Dexamethasone
Dexamethasone for the treatment of depression: a preliminary report. Arana, July 304–306

Diagnosis, Classification
Defining *recovery* and *remission* [letter]. Shrader; Kupfer reply, Oct 433–434
Is the tendency to weep one of the most useful indicators for depressed mood [letter]? Okada, Aug 351–352

Diagnosis, Differential
Ganser's syndrome clarification [letter]. Cocores; Grieger reply, Apr 185–186
Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. Fallon, Nov 457–460
Speech pauses and diagnosis [letter]. Friedman, Apr 181–182

Dose-Response Relationship
Dose response effects of zolpidem in normal geriatric subjects. Scharf, Feb 77–83

Doxepin
Is doxepin a safer tricyclic for the heart? Roose, Aug 338–341

Dreams and Dreaming
Fluoxetine and dreaming [letter]. Markowitz, Oct 432

Drug Interactions
Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Goldbloom, June 261–262
Augmentation regimens for depression. Nemeroff, May suppl 21–27
Case of mania as a result of fluoxetine-marijuana interaction [letter]. Stoll, June 280–281
Case report of cimetidine-induced clozapine toxicity. Szymanski, Jan 21–22
Effect of phenytoin on plasma clozapine concentrations in two patients. Miller, Jan 23–25
Raised serum levels of desipramine with the antiarrhythmic propafenone [letter]. Katz, Oct 432–433
Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. Feder, Apr 163–164

Drug Levels see Blood Levels

Drug Side Effects
Antidepressant adverse drug reactions. Nierenberg, June suppl 40–47
Antidepressant treatment and side effect considerations. Tollefson, May suppl 4–13
Beneficial and adverse effects of hypnotics. Balter, July suppl 16–23
Fluoxetine versus trazodone: efficacy and activating-sedating effects. Beasley Jr, July 294–299
Polyarthritis: an unusual side effect of lithium [letter]. Khanna, Jan 43–44
Residual effects of hypnotics: an update. Hindmarch, July suppl 14–15
Tinnitus related to bupropion treatment [letter]. Settle Jr, Aug 352

Drug Therapy, Combination
Rapid treatment of depression with selegiline-phenylalanine combination [letter]. Sabelli, Mar 137
Strategies for fluoxetine-MAOI combination therapy [letter]. Peterson; Boyer reply, Feb 87–88

Dyskinesia, Drug-Induced
Clozapine and jaw dyskinesia: a case report. de Leon, Dec 494–495

Eating Disorders see also Anorexia Nervosa, Bulimia
Family-genetic studies of eating disorders. Strober, Oct suppl 9–12
Hyperamylasemia and salivary gland enlargements in patients with eating disorders [letter]. Kinzl, Mar 139–140
Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. Hernandez, Dec suppl 32–40
Stealing in eating disordered patients. Krahn, Mar 112–115

Editorials
Auld Lang Syne [editorial]. Gelenberg, Feb 54–55
Holiday greetings [editorial]. Gelenberg, Dec 489–490
Psychiatry in the 1990s [editorial]. Gelenberg, May 205–207
Psychiatry, psychology, and psychopharmacology [editorial]. Gelenberg, Jan 3

Electrical Trauma
Electrical trauma, nonictal EEG changes, and mania: a case report [letter]. Khanna, June 280

Electroconvulsive Therapy
ECT response and blood pressure reduction [letter]. Masiar; Swartz reply, Apr 183
Labetalol and ECT [letter]. Kellner; Knos reply, Sept 386–388
Labetalol and ECT [letter]. Silver; Knos reply, Sept 387–388

Epilepsy
Lifetime history of panic attacks and epilepsy: an association from a general population survey [letter]. Pariente, Feb 88–89

Exposure Therapy
Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. O'Sullivan, Apr 150–155

Extrapyramidal Side Effects
Neuroleptic malignant syndrome: long-term follow-up of 20 cases. Pope Jr, May 208–212

Fatigue
Overview of chronic fatigue syndrome. Krupp, Oct 403–410

Fetishism
Fluoxetine treatment of a fetish [letter]. Lorefice, Jan 41

Flooding Therapy
Psychiatric complications during flooding therapy for posttraumatic stress disorder. Pitman, Jan 17–20

Fluoxetine
Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Goldbloom, June 261–262
Bradycardia and syncope induced by fluoxetine [letter]. Feder; Ellison reply, Mar 139
Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. Jenike, Jan 13–14
Case of mania as a result of fluoxetine-marijuana interaction [letter]. Stoll, June 280–281
Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. Fabre, June suppl 62–67
Does fluoxetine induce suicidality [letter]? Brewerton; Fava reply, Nov 479–480
Double-blind comparison of bupropion and fluoxetine in depressed outpatients. Feighner, Aug 329–335
Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. Buff, Apr 174–176
Efficacy and safety of morning versus evening fluoxetine administration. Usher, Mar 134–136
Fluoxetine and dreaming [letter]. Markowitz, Oct 432
Fluoxetine in anorexia nervosa [letter]. Lee; Gwirtsman reply, May 240–241
Fluoxetine in the treatment of late luteal phase dysphoric disorder. Stone, July 290–293
Fluoxetine-induced bradycardia [letter]. Friedman; Buff reply, Nov 477
Fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. Hoehn-Saric, Mar 131–133
Fluoxetine treatment of a fetish [letter]. Lorefice, Jan 41
Fluoxetine treatment of cocaine abuse in heroin addicts. Pollack, Jan 31–33
Fluoxetine treatment of depressive symptoms in acute intermittent porphyria [letter]. Vaz, Mar 138
Fluoxetine treatment of trichotillomania [letter]. Alexander, Feb 88
Fluoxetine versus trazodone: efficacy and activating-sedating effects. Beasley Jr, July 294–299
Obsessive compulsive disorder, depression, and fluoxetine. Hollander, Oct 418–422

Open trial of fluoxetine in patients with anorexia nervosa. Kaye, Nov 464–471
Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. Rothschild, Dec 491–493
Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. Feder, Apr 163–164
Role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. Zajecka, Feb 66–68
Role of the right hemisphere in fluoxetine-induced bradycardia and syncope [letter]. Friedman, Mar 138–139
Strategies for fluoxetine-MAOI combination therapy [letter]. Peterson; Boyer reply, Feb 87–88
Suicidality and fluoxetine: is there a relationship? Fava, Mar 108–111
Three cases of paraphilias responsive to fluoxetine treatment. Perilstein, Apr 169–170
Treatment of trichotillomania with fluoxetine [letter]. Stanley, June 282
Unexpected deaths in depressed medical inpatients treated with fluoxetine. Spier, Sept 377–382

Flurazepam
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the multiple sleep latency test. Dement, Sept suppl 31–37
Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics. Hilbert, Sept suppl 21–26

Follow-Up Studies
Neuroleptic malignant syndrome: long-term follow-up of 20 cases. Pope Jr, May 208–212
Outcome and clinical course in inpatient bulimic women: a 2- to 9-year follow-up study. Fallon, June 272–278
Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. O'Sullivan, Apr 150–155

GABA
Lorazepam and catatonia [letter]. Menza; Rosebush reply, Apr 186–188

Ganser's Syndrome
Ganser's syndrome clarification [letter]. Cocores; Greiger reply, Apr 185–186

Generalized Anxiety Disorder see Anxiety

Genetics
Family-genetic studies of eating disorders. Strober, Oct suppl 9–12

Geriatric Psychiatry
Acute open-trial nortriptyline therapy of bereavement-related depression in late life. Pasternak, July 307–310
Cerebral infarct presenting as mania [letter]. Fawcett, Aug 352–353
Dose response effects of zolpidem in normal geriatric subjects. Scharf, Feb 77–83
Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. Buff, Apr 174–176
Fluoxetine-induced bradycardia [letter]. Fishbain; Fogel reply, Nov 477–478
Lithium toxicity in an elderly woman [letter]. Bassingthwaighte, Apr 181
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the multiple sleep latency test. Dement, Sept suppl 31–37
Recognition and treatment of depression in the elderly. Small, June suppl 11–22

Gilles de la Tourette's Disease
Obsessional severity in Tourette's syndrome [letter]. Stein, Sept 388
Tourette's syndrome in the developmentally disabled [letter]. Shaktman; Comings reply, June 279

Grief
Acute open-trial nortriptyline therapy of bereavement-related depression in late life. Pasternak, July 307–310
Anxiety disorders during acute bereavement [letter]. Friedman; Jacobs reply, May 241

Hair Pulling see Trichotillomania

Haloperidol
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. Alphs, Aug 346–348
Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Salzman, Apr 177–180

Heart Disease
Fluoxetine-induced bradycardia [letter]. Friedman; Buff reply, Nov 477

Heroin
Fluoxetine treatment of cocaine abuse in heroin addicts. Pollack, Jan 31–33

Human Immunodeficiency Virus
New-onset psychosis in HIV-infected patients. Harris, Sept 369–376
Relationship of coping style to affective state and perceived social support in asymptomatic and symptomatic HIV-infected persons: implications for clinical management. Wolf, Apr 171–173

Hyperamylasemia
Hyperamylasemia and salivary gland enlargements in patients with eating disorders [letter]. Kinzl, Mar 139–140

Hypertension
Susceptibility to spontaneous MAOI hypertensive episodes [letter]. Zajecka, Dec 513–514

Hypochondriasis
Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. Fallon, Nov 457–460
Pimozide in clinical psychiatry [letter]. Phillips; Opler reply, Dec 514–515

Hypothyroidism
Pseudotumor cerebri associated with lithium therapy in two patients [letter]. Dommisse; Levine reply, May 239

Imipramine
Long-term follow-up of chronic depression treated with imipramine. Kocsis, Feb 56–59
Painful ejaculation associated with antidepressants in four patients. Aizenberg, Nov 461–463
Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Deltito, Mar 121–127

Insomnia
Appropriate use of benzodiazepines in insomnia: clinical update. Hishikawa, July suppl 10–13
Beneficial and adverse effects of hypnotics. Balter, July suppl 16–23
Diagnosis and treatment of insomnia and depression. Ware, June suppl 55–61
Introduction. Anxiety and insomnia: current trends in research and therapeutics. Hishikawa, July suppl 3–4
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the multiple sleep latency test. Dement, Sept suppl 31–37
Residual effects of hypnotics: an update. Hindmarch, July suppl 14–15
Summary. Anxiety and insomnia: current trends in research and therapeutics. Hishikawa, July suppl 27

Irritable Bowel Syndrome
Open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. Tollefson, Dec 502–508

Journal of Clinical Psychiatry
Auld Lang Syne [editorial]. Gelenberg, Feb 54–55
Holiday greetings [editorial]. Gelenberg, Dec 489–490

Kindling
Valproate in combat-related posttraumatic stress disorder. Fesler, Sept 361–364

Labetalol
Labetalol and ECT [letter]. Kellner; Knos reply, Sept 386–388
Labetalol and ECT [letter]. Silver; Knos reply, Sept 387–388

Late Luteal Phase Dysphoric Disorder see Premenstrual Syndrome

Light Therapy
Bright light augmentation in antidepressant nonresponders. Levitt, Aug 336–337
Phototherapeutic response variability in seasonal affective disorder [letter]. Rice, Aug 349

Lithium
Lithium toxicity in an elderly woman [letter]. Bassingthwaighte, Apr 181
Lithium treatment of chronic hair pulling. Christenson, Mar 116–120
Lithium use and pregnancy [letter]. Shafey; Schou reply, June 279
Polyarthritis: an unusual side effect of lithium [letter]. Khanna, Jan 43–44
Pseudotumor cerebri associated with lithium therapy in two patients [letter]. Dommisse; Levine reply, May 239

Lorazepam
Lorazepam and catatonia [letter]. Menza; Rosebush reply, Apr 186–188
Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Salzman, Apr 177–180

Mania
Case of mania as a result of fluoxetine-marijuana interaction [letter]. Stoll, June 280–281
Cerebral infarct presenting as mania [letter]. Fawcett, Aug 352–353
Changing psychiatric symptoms in a patient with vitamin B_{12} deficiency [letter]. Verbanck, Apr 182–183
Electrical trauma, nonictal EEG changes, and mania: a case report [letter]. Khanna, June 280
Four cases of obstructive sleep apnea associated with treatment-resistant mania. Strakowski, Apr 156–158

Maprotiline
Prophylactic efficacy of maprotiline on unipolar depression relapse. Rouillon, Oct 423–431

Medical Illness
Comorbidity and medical complications of bulimia nervosa. Mitchell, Oct suppl 13–20
Methylphenidate in depressed medically ill patients. Rosenberg, June 263–267
Unexpected deaths in depressed medical inpatients treated with fluoxetine. Spier, Sept 377–382

Melancholia see Depression

Menstrual Cycle
Menstrual irregularities associated with bupropion treatment. Halbreich, Jan 15–16

Mental Retardation
Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. Ratey, Apr 159–162
Methadone
Fluoxetine treatment of cocaine abuse in heroin addicts. Pollack, Jan 31–33
Methylphenidate
Methylphenidate in depressed medically ill patients. Rosenberg, June 263–267
MHPG
Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. Keck Jr, June 250–254
Misidentification
Neuroanatomical correlates of clinical misidentification and misperception in senile dementia of the Alzheimer type. Förstl, June 268–271
Monoamine Oxidase Inhibitors
Gastric absorption of nifedipine [letter]. Ward, Apr 188
MAOI and monosodium glutamate interaction [letter]. Lee, Jan 43
Panic disorder: a treatment update. Burrows, July suppl 24–26
Strategies for fluoxetine-MAOI combination therapy [letter]. Peterson; Boyer reply, Feb 87–88
Susceptibility to spontaneous MAOI hypertensive episodes [letter]. Zajecka, Dec 513–514
Monosodium Glutamate
MAOI and monosodium glutamate interaction [letter]. Lee, Jan 43
More on the effects of monosodium glutamate [letter]. Samuels; Balon reply, Aug 350–351
Nadolol
Placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. Wells, June 255–260
Neuroleptic Malignant Syndrome
Brachial plexopathy complicating neuroleptic malignant syndrome [letter]. Lazarus, May 239–240
Bromocriptine and neuroleptic malignant syndrome [letter]. Rosebush, Jan 41–42
Case of clozapine-induced neuroleptic malignant syndrome. Miller, Mar 99–101
Clozapine-induced neuroleptic malignant syndrome. DasGupta, Mar 105–107
Neuroleptic malignant syndrome associated with clozapine use. Anderson, Mar 102–104
Neuroleptic malignant syndrome: long-term follow-up of 20 cases. Pope Jr, May 208–212
Nifedipine
Gastric absorption of nifedipine [letter]. Ward, Apr 188
Norepinephrine
Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. Keck Jr, June 250–254
Nortriptyline
Acute open-trial nortriptyline therapy of bereavement-related depression in late life. Pasternak, July 307–310
Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. Fabre, June suppl 62–67
Nurses
Nurse clinical-specialists as nonphysician prescribers [letter]. Sovner; Pies reply, Dec 515
Obsessive Compulsive Disorder
Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. Jenike, Jan 13–14
Clomipramine in obsessive compulsive disorder [letter]. Lee; Greist reply, Apr 183–185
Fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. Hoehn-Saric, Mar 131–133
Fluoxetine treatment of a fetish [letter]. Lorefice, Jan 41
Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. Fallon, Nov 457–460
Obsessional severity in Tourette's syndrome [letter]. Stein, Sept 388
Obsessive compulsive disorder, depression, and fluoxetine. Hollander, Oct 418–422
Potential antidopaminergic effects of serotonin reuptake inhibitors [letter]. Kim, Jan 42
Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. O'Sullivan, Apr 150–155
Organic Mental Disorders
New-onset psychosis in HIV-infected patients. Harris, Sept 369–376
Panic
Abstract presentation. The pathophysiology of panic anxiety. Klein, Feb suppl 10–11
Behavioral inhibition in children: a possible precursor to panic disorder or social phobia. Rosenbaum, Nov suppl 5–9
Clobazam and panic disorder [letter]. Name Withheld Upon Request, Jan 44
Conclusions. Panic disorder: strategies for long-term treatment. Klerman, Feb suppl 33
Decisions for the clinician in the treatment of panic disorder: when to treat, which treatment to use, and how long to treat. Schatzberg, Feb suppl 26–31
Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. Tesar, Feb 69–76
Introduction. Panic disorder: strategies for long-term treatment. Klerman, Feb suppl 3–5
Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. Kupfer, Feb suppl 12–16
Lifetime history of panic attacks and epilepsy: an association from a general population survey [letter]. Pariente, Feb 88–89
Long-term pharmacologic treatment of panic disorder. Ballenger, Feb suppl 18–23
Overview of anxiety disorders: prevalence, biology, course, and treatment. Schatzberg, July suppl 5–9
Panic disorder: a treatment update. Burrows, July suppl 24–26
Panic disorder: impact on quality of life. Weissman, Feb suppl 6–8
Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Deltito, Mar 121–127
Phenomenology and neurobiology of social phobia: comparison with panic disorder. Uhde, Nov suppl 31–40
Speech pauses and diagnosis [letter]. Friedman, Apr 181–182
Surreptitious drug use by panic disorder patients [letter]. Clark; Deltito reply, Oct 434
Paranoia
Changing psychiatric symptoms in a patient with vitamin B_{12} deficiency [letter]. Verbanck, Apr 182–183
Patient Education
Malingering [letter]. Sheeley; Yudofsky reply, June 281–282
Pergolide
Pergolide mesylate treatment of cocaine withdrawal. Malcolm, Jan 39–40
Personality Disorder
Fluoxetine-induced bradycardia [letter]. Fishbain; Fogel reply, Nov 477–478
L-Phenylalanine
Rapid treatment of depression with selegiline-phenylalanine combination [letter]. Sabelli, Mar 137; Correction, May 241
Phenytoin
Effect of phenytoin on plasma clozapine concentrations in two patients. Miller, Jan 23–25
Phobia
Behavioral inhibition in children: a possible precursor to panic disorder or social phobia. Rosenbaum, Nov suppl 5–9
Brief Social Phobia Scale. Davidson, Nov suppl 48–51
Introduction. Social phobia in review. Davidson, Nov suppl 3–4
Levels of urinary free cortisol in social phobia. Potts, Nov suppl 41–42
Long-term treatment of social phobia with clonazepam. Davidson, Nov suppl 16–20
New developments in cognitive-behavioral therapy for social phobia. Heimberg, Nov suppl 21–30
Phenomenology and neurobiology of social phobia: comparison with panic disorder. Uhde, Nov suppl 31–40
Questions and answers. Social phobia: advances in understanding and treatment. Nov suppl 52–54
Social phobia: the Anxiety Disorders Association of America helps raise the veil of ignorance. Ross, Nov suppl 43–47
Treatment of social phobia with drugs other than benzodiazepines. Liebowitz, Nov suppl 10–15
Phototherapy
Ultraviolet versus non-ultraviolet light therapy for seasonal affective disorder. Lam, May 213–216
Physostigmine
Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. Sevush, July 300–303
Pimozide
Pimozide in clinical psychiatry [letter]. Phillips; Opler reply, Dec 514–515
Role of pimozide in clinical psychiatry: a review. Opler, May 221–233
Posttraumatic Stress Disorder
Alexithymia and posttraumatic stress disorder [letter]. Alvarez; Hyer reply, July 317–318
Psychiatric complications during flooding therapy for posttraumatic stress disorder. Pitman, Jan 17–20
Valproate in combat-related posttraumatic stress disorder. Fesler, Sept 361–364
Pregnancy
Lithium use and pregnancy [letter]. Shafey; Schou reply, June 279
Premenstrual Syndrome
Fluoxetine in the treatment of late luteal phase dysphoric disorder. Stone, July 290–293
Propafenone
Raised serum levels of desipramine with the antiarrhythmic propafenone [letter]. Katz, Oct 432–433
Pseudotumor Cerebri
Pseudotumor cerebri associated with lithium

therapy in two patients [letter]. Dommisse; Levine reply, May 239
Psychologists
"Deep structure" of clinical medicine and prescribing privileges for psychologists [special article]. Pies, Jan 4–8
Deep structures of psychology and prescribing: more than a superficial look [commentary]. Evans, Jan 9–10
Nurse clinical-specialists as nonphysician prescribers [letter]. Sovner; Pies reply, Dec 515
Prescribing privileges for psychologists [letter]. Charatan, Sept 388
Prescribing privileges for psychologists [letter]. Metz; Pies reply, July 312–313
Prescribing privileges for psychologists [letters]. Dawson; Landy; Pies reply, July 311–312
Prescribing privileges for psychologists [letters]. Kasparek; Jonas; Clark; Smith; Heckmann; Pies reply, July 313–316
Prescribing privileges for psychologists [letters]. Metz; Landy; Smith; Clark; Jonas; Dawson; Kasparek; D'Afflitti reply, July 311–317
Profoundly different professions: commentary on prescribing privileges for psychologists [commentary]. D'Afflitti, Jan 11–12
Psychiatry, psychology, and psychopharmacology [editorial]. Gelenberg, Jan 3
Psychosis
New-onset psychosis in HIV-infected patients. Harris, Sept 369–376
Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Salzman, Apr 177–180
Prolonged cocaine psychosis implies underlying major psychopathology [letter]. Satel, Aug 349–350
Psychosocial Therapy
New developments in cognitive-behavioral therapy for social phobia. Heimberg, Nov suppl 21–30
Nonpharmacologic treatments of bulimia nervosa. Agras, Oct suppl 29–33
Psychotic Disorders
Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. McElroy, Oct 411–414
Cocaine-induced psychosis. Brady, Dec 509–512
Pimozide in clinical psychiatry [letter]. Phillips; Opler reply, Dec 514–515
Psychotropic Drugs
P.R.N. medications in child psychiatric patients: a pilot placebo-controlled study. Vitiello, Dec 499–501
Quazepam
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the multiple sleep latency test. Dement, Sept suppl 31–37
Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics. Hilbert, Sept suppl 21–26
Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. Wamsley, Sept suppl 15–20
Raynaud's Phenomenon
New onset Raynaud's Phenomenon in a schizophrenic patient [letter]. McCance-Katz, Feb 89–90
Receptors, Benzodiazepine
Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. Wamsley, Sept suppl 15–20
Receptors, Serotonin
Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. Azmitia, Dec suppl 4–16
Behavioral studies of serotonin receptor agonists as antidepressant drugs. Lucki, Dec suppl 24–31
Serotonin uptake inhibitors: effects on motivated consummatory behaviors. Amit, Dec suppl 55–60
Schizophrenia
Brain abnormalities in schizophrenia [letter]. Friedman; Joseph reply, Jan 43
Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. McElroy, Oct 411–414
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. Alphs, Aug 346–348
New onset Raynaud's Phenomenon in a schizophrenic patient [letter]. McCance-Katz, Feb 89–90
Paranoid schizophrenia in adolescence. Apter, Sept 365–368
Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. Cleghorn, Jan 26–30
Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. Kafka, Feb 60–65
Supersensitivity psychosis [letter]. Peet; Simpson reply, Feb 90
Seasonal Affective Disorder
Environmental influences on the onset of winter depression [letter]. Mayor, Nov 480
Phototherapeutic response variability in seasonal affective disorder [letter]. Rice, Aug 349
Ultraviolet versus non-ultraviolet light therapy for seasonal affective disorder. Lam, May 213–216
Sedative Hypnotics
Beneficial and adverse effects of hypnotics. Balter, July suppl 16–23
Benzodiazepine hypnotics: sorting the pharmacokinetic facts. Greenblatt, Sept suppl 4–10
Criteria for selection of appropriate benzodiazepine hypnotic therapy. Mendels, Sept suppl 42–46
Determinants of pharmacologic effects and toxicity of benzodiazepine hypnotics: role of lipophilicity and plasma elimination rates. Arnold, Sept suppl 11–14
Introduction. Benzodiazepine hypnotics: the interface of basic and clinical science. Greenblatt, Sept suppl 3
Introduction. Overview of the efficacy and safety of benzodiazepine hypnotics using objective methods. Dement, Sept suppl 27–30
Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. Wamsley, Sept suppl 15–20
Residual effects of hypnotics: an update. Hindmarch, July suppl 14–15
Review of the safety profiles of benzodiazepine hypnotics. Roth, Sept suppl 38–41
Seizures
102-center prospective study of seizure in association with bupropion. Johnston, Nov 450–456
Selegiline
Rapid treatment of depression with selegiline-phenylalanine combination [letter]. Sabelli, Mar 137; Correction, May 241
Use of selegiline in Alzheimer's patients with behavior problems. Goad, Aug 342–345
Serotonin
Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Goldbloom, June 261–262
Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. Azmitia, Dec suppl 4–16
Behavioral studies of serotonin receptor agonists as antidepressant drugs. Lucki, Dec suppl 24–31
Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. Hernandez, Dec suppl 32–40
Introduction. Multiple roles and actions of serotonin systems. Meltzer, Dec suppl 3
Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. Sellers, Dec suppl 49–54
Role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. Zajecka, Feb 66–68
Role of serotonin in therapy of depression and related disorders. Fuller, May suppl 52–57
Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood. Kaye, Dec suppl 41–48
Serotonin and behavior: emphasis on motor control. Jacobs, Dec suppl 17–23
Serotonin, suicide, and aggression: clinical studies. Golden, Dec suppl 61–69
Serotonin uptake inhibitors: effects on motivated consummatory behaviors. Amit, Dec suppl 55–60
Summary. The significance of serotonin for neuropsychiatric disorders. Meltzer, Dec suppl 70–72
Sertraline
Effects of placebo washout and dose in a comparison of sertraline and amitriptyline [letter]. Karagianis; Reimherr reply, Sept 386
Sexual Differences
Anxiety disorders during acute bereavement [letter]. Friedman; Jacobs reply, May 241
Sexual Disorders
Three cases of paraphilias responsive to fluoxetine treatment. Perilstein, Apr 169–170
Sexual Dysfunction
Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. Goldbloom, June 261–262
Painful ejaculation associated with antidepressants in four patients. Aizenberg, Nov 461–463
Role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. Zajecka, Feb 66–68
Sialadenosis
Hyperamylasemia and salivary gland enlargements in patients with eating disorders [letter]. Kinzl, Mar 139–140
Sleep Apnea
Four cases of obstructive sleep apnea associated with treatment-resistant mania. Strakowski, Apr 156–158
Social Phobia see Phobia
Stroke
Speech hesitation pauses as markers for mood disorder in stroke patients [letter]? Friedman; Robinson reply, Mar 140
Substance Abuse
Cocaine-induced psychosis. Brady, Dec 509–512
Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. Sellers, Dec suppl 49–54
Substance abuse and schizophrenia: effect on

symptoms but not on neurocognitive function. Cleghorn, Jan 26–30
Substance Withdrawal Syndrome
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. Alphs, Aug 346–348
Suicide
Does fluoxetine induce suicidality [letter]? Brewerton; Fava reply, Nov 479–480
Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. Rothschild, Dec 491–493
Serotonin, suicide, and aggression: clinical studies. Golden, Dec suppl 61–69
Suicidality and fluoxetine: is there a relationship? Fava, Mar 108–111
Supersensitivity Psychosis
Supersensitivity psychosis [letter]. Peet; Simpson reply, Feb 90
Tests, Polysomnographic
Introduction. Overview of the efficacy and safety of benzodiazepine hypnotics using objective methods. Dement, Sept suppl 27–30
Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the multiple sleep latency test. Dement, Sept suppl 31–37
Tests, Psychological
Alexithymia and posttraumatic stress disorder [letter]. Alvarez; Hyer reply, July 317–318
Brief Social Phobia Scale. Davidson, Nov suppl 48–51
Obsessional severity in Tourette's syndrome [letter]. Stein, Sept 388
Thrombocytopenia
Thrombocytopenia associated with carbamazepine: a case series. Tohen, Dec 496–498
Thromboembolism
Thromboembolism complicating psychiatric stupor [letter]. O'Brien, Mar 137–138
Tinnitus
Tinnitus related to bupropion treatment [letter]. Settle Jr, Aug 352
Toxicity
Lithium toxicity in an elderly woman [letter]. Bassingthwaighte, Apr 181
Unexpected deaths in depressed medical inpatients treated with fluoxetine. Spier, Sept 377–382
Tranquilizing Agents, Major
Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. Alphs, Aug 346–348
Neuroleptic malignant syndrome: long-term follow-up of 20 cases. Pope Jr, May 208–212
Placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. Wells, June 255–260
Tranylcypromine
Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. Keck Jr, June 250–254
Trazodone
Fluoxetine versus trazodone: efficacy and activating-sedating effects. Beasley Jr, July 294–299
Trichotillomania
Clomipramine treatment of trichotillomania [letter]. Friedman, Nov 478–479
Clomipramine treatment of trichotillomania: a follow-up report on four cases. Pollard, Mar 128–130
Estimated lifetime prevalence of trichotillomania in college students. Christenson, Oct 415–417
Fluoxetine treatment of trichotillomania [letter]. Alexander, Feb 88
Lithium treatment of chronic hair pulling. Christenson, Mar 116–120
Treatment of trichotillomania with fluoxetine [letter]. Stanley, June 282
Tyramine
MAOI and monosodium glutamate interaction [letter]. Lee, Jan 43
Ultraviolet Therapy
Ultraviolet versus non-ultraviolet light therapy for seasonal affective disorder. Lam, May 213–216
Valproate
Valproate in combat-related posttraumatic stress disorder. Fesler, Sept 361–364
Violence
Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. Ratey, Apr 159–162
P.R.N. medications in child psychiatric patients: a pilot placebo-controlled study. Vitiello, Dec 499–501
Serotonin, suicide, and aggression: clinical studies. Golden, Dec suppl 61–69
Vitamins
Changing psychiatric symptoms in a patient with vitamin B_{12} deficiency [letter]. Verbanck, Apr 182–183
Women
De Clérambault's syndrome in sexually experienced women. Giannini, Feb 84–86
Zolpidem
Dose response effects of zolpidem in normal geriatric subjects. Scharf, Feb 77–83

Journal of Clinical Psychiatry

Author Index to Volume 52: January 1991 Through December 1991

Agras WS. Nonpharmacologic treatments of bulimia nervosa. Oct suppl 29–33
Ahmed I see Rosenberg PB
Aizenberg D, Zemishlany Z, Hermesh H, Karp L, Weizman A. Painful ejaculation associated with antidepressants in four patients. Nov 461–463
Aizley HG see McElroy SL; Pope HG Jr
Alarcon RD. Review of Maser JD, Cloninger CR (eds): *Cormorbidity of Mood and Anxiety Disorders*. Feb 91
Alexander RC. Fluoxetine treatment of trichotillomania [letter]. Feb 88
Alpert JE see Strakowski SM
Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. Aug 346–348
Altman B see Pitman RK
Alvarez WA, Shipko S. Alexithymia and posttraumatic stress disorder [letter with reply]. July 317
Amit Z, Smith BR, Gill K. Serotonin uptake inhibitors: effects on motivated consummatory behaviors. Dec suppl 55–60
Amsterdam JD see Rickels K
Anderson ES, Powers PS. Neuroleptic malignant syndrome associated with clozapine use. Mar 102–104
Apter A, Spivak B, Weizman A, Tyano S, Orvaschel H. Paranoid schizophrenia in adolescence. Sept 365–368
Arana GW, Forbes RA. Dexamethasone for the treatment of depression: a preliminary report. July 304–306
Argyle N see Deltito JA
Arheart KL see Wells BG
Arnold J. Determinants of pharmacologic effects and toxicity of benzodiazepine hypnotics: role of lipophilicity and plasma elimination rates. Sept suppl 11–14
Ascher JA see Feighner JP; Johnston JA
Ayubi MA see Wells BG
Azmitia EC, Whitaker-Azmitia PM. Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. Dec suppl 4–16
Baer L see Jenike MA
Bailey KP see Sovner R
Bakhai Y see Halbreich U
Ballenger JC. Long-term pharmacologic treatment of panic disorder. Feb suppl 18–23
Ballenger JC see Brady KT; Malcolm R; Schatzberg AF
Balon R, Pohl R, Yeragani VK, Berchou R. Reply to Samuels A: More on the effects of monosodium glutamate [letter]. Aug 350–351
Balson PM see Wolf TM
Balter MB, Uhlenhuth EH. Beneficial and adverse effects of hypnotics. July suppl 16–23
Baptista T see Hernandez L
Barlow DH see Côté G; Heimberg RG
Bassingthwaighte ME, Rummans TA. Lithium toxicity in an elderly woman [letter]. Apr 181
Batey SR see Feighner JP
Battista D see Hilbert JM
Battle AO. Review of Fromm E, Kahn S: *Self-Hypnosis: The Chicago Paradigm*. Mar 142–143
Battle AO. Review of Yapko MD: *Trancework: An Introduction to the Practice of Clinical Hypnosis*. Nov 482–483
Beasley CM Jr, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetine versus trazodone: efficacy and activating-sedating effects. July 294–299
Beasley CM Jr see Usher RW
Behar D see Vitiello B
Beitman BD. Review of Manning DW, Francis AJ (eds): *Combined Pharmacotherapy and Psychotherapy for Depression*. Nov 481
Berchou R see Balon R
Biebl W see Kinzl J
Biederman J see Rosenbaum JF
Bielski RJ see Mayor J; Rice J
Billings CK. Review of Easson WM, Rock NL: *Psychiatry Specialty Board Review*. Aug 355
Billings CK. Review of Skodol AE: *Problems in Differentiäl Diagnosis: From DSM-III to DSM-III-R in Clinical Practice*. Jan 46–47
Black B see Uhde TW
Bolduc EA see Rosenbaum JF
Bosomworth JC see Beasley CM Jr; Usher RW
Bowers TC see Stanley MA
Boyce P see Cullen M
Boyer WF, Feighner JP. Reply to Peterson GN: Strategies for fluoxetine-MAOI combination therapy [letter]. Feb 87–88
Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. Dec 509–512
Brenner R see Buff DD
Brewerton TD. Does fluoxetine induce suicidality [letter with reply]? Nov 479–480
Brodaty H see Cullen M
Bronson SS see Pollard CA
Brown CS see Wells BG
Brown GM see Cleghorn JM
Brown TM see Uhde TW
Brown WA see Stone AB
Bruhn M see Weiner MF
Bruun RD see Stein DJ
Buchanan A see Lam RW
Buff DD, Brenner R, Kirtane SS. Reply to Friedman EH: fluoxetine-induced bradycardia [letter]. Nov 477
Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. Apr 174–176
Bulik CM see Kaye WH
Burns A see Förstl H
Burrows GD, Norman TR, Judd FK. Panic disorder: a treatment update. July suppl 24–26
Buttolph L see Jenike MA
Buysse DJ see Pasternak RE
Camargo EE see Hoehn-Saric R
Campeas R see Liebowitz MR
Camuñas C see de Leon J
Carter WP see Keck PE Jr
Castillo J see Tohen M
Chaloff J see Rosenbaum JF
Charatan FB. Prescribing privileges for psychologists [letter]. Sept 388
Charney DS see Satel SL
Chatterjee S see Khanna R
Christenson GA, Popkin MK, Mackenzie TB, Realmuto GM. Lithium treatment of chronic hair pulling. Mar 116–120
Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. Oct 415–417
Chu C-C see Wells BG
Clark CM see Lam RW
Clark DB. Prescribing privileges for psychologists [letter with reply]. July 314–317
Clark DB. Surreptitious drug use by panic disorder patients [letter with reply]. Oct 434
Clary C see Rickels K
Clayton AH see Grieger TA
Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. Jan 26–30
Cocores JA. Ganser's syndrome clarification [letter with reply]. Apr 185–186
Cohen LS see Tesar GE
Cold JA see Wells BG
Cole JO see McElroy SL; Nierenberg AA; Stoll AL; Tohen M
Comings BG see Comings DE
Comings DE, Comings BG, Himes JA. Reply to Shaktman D: Tourette's syndrome in the developmentally disabled [letter]. June 279
Cooper T see Szymanski S
Cooper TB see Keck PE Jr
Corrigan MHN see Golden RN
Côté G, Barlow DH. Review of Kennerley H: *Managing Anxiety: A Training Manual*. June 284

Cowie D. Review of the Committee on the College Student of the Group for the Advancement of Psychiatry: *Psychotherapy With College Students*. Nov 481–482
Cox CS see Hoehn-Saric R
Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, Wilhelm K. Carbamazepine for treatment-resistant melancholia. Nov 472–476
Cunningham E see Vitiello B
D'Afflitti JP. Profoundly different professions: commentary on prescribing privileges for psychologists [commentary]. Jan 11–12
D'Afflitti JP. Reply to Metz A; Landy DA; Smith JM; Clark DB; Jonas AG; Dawson G; Kasparek C: Prescribing privileges for psychologists [letters]. July 311–317
Dalack GW see Roose SP
Das A see Khanna R
DasGupta K, Young A. Clozapine-induced neuroleptic malignant syndrome. Mar 105–107
Davidson J see Johnston JA
Davidson JRT. Introduction. Social phobia in review. Nov suppl 3–4
Davidson JRT, Ford SM, Smith RD, Potts NLS. Long-term treatment of social phobia with clonazepam. Nov suppl 16–20
Davidson JRT, Potts NLS, Richichi EA, Ford SM, Krishnan KRR, Smith RD, Wilson W. Brief Social Phobia Scale. Nov suppl 48–51
Davidson JRT see Potts NLS
Davidson RC see Ward NG
Davis CM see Goad DL
Dawson G. Prescribing privileges for psychologists [letter with reply]. July 311–317
DeCaria CM see Hollander E
de Leon J, Moral L, Camuñas C. Clozapine and jaw dyskinesia: a case report. Dec 494–495
de los Heros R see Tohen M
Deltito JA. Reply to Clark DB: Surreptitious drug use by panic disorder patients [letter]. Oct 434
Deltito JA, Argyle N, Klerman GL. Patients with panic disorder unaccompanied by depression improve with alprazolam and imipramine treatment. Mar 121–127
Deltito JA, Panarites HC. Review of Hollander MH, Ford CV: *Dynamic Psychotherapy: An Introductory Approach*. Apr 192
Dement WC. Introduction. Overview of the efficacy and safety of benzodiazepine hypnotics using objective methods. Sept suppl 27–30
Dement WC. Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the multiple sleep latency test. Sept suppl 31–37
Dennett DE. Review of Goldstein S, Goldstein M: *Managing Attention Disorders in Children*. Mar 143
Dessain EC see McElroy SL
de Zwaan M see Mitchell JE
Dommisse J. Pseudotumor cerebri associated with lithium therapy in two patients [letter with reply]. May 239
Doraiswamy PM see Potts NLS
Dornseif BE see Beasley CM Jr
Dralle PW see Wolf TM
Drewnowski A see Krahn DD
Dunner DL. Depression: challenges for the future. May suppl 44–51
Dunsmore G see Tollefson GD
Dysken MW see Kim SW
Ekstrom RD see Golden RN
Elia J see Vitiello B
Ellison JM, Ely E, Milofsky JE. Reply to Feder R: Bradycardia and syncope induced by fluoxetine [letter]. Mar 139
Ely E see Ellison JM
Evans MK. Deep structures of psychology and prescribing: more than a superficial look [commentary]. Jan 9–10
Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. June suppl 62–67
Fallon BA, Javitch JA, Hollander E, Liebowitz MR. Hypochondriasis and obsessive compulsive disorder: overlaps in diagnosis and treatment. Nov 457–460
Fallon BA, Walsh BT, Sadik C, Saoud JB, Lukasik V. Outcome and clinical course in inpatient bulimic women: a 2- to 9-year follow-up. June 272–278
Fallon BA see Liebowitz MR
Farrer RJ see Tohen M
Fast GA see Preskorn SH
Fava M, Rosenbaum JF. Reply to Brewerton TD: Does fluoxetine induce suicidality [letter]? Nov 479–480
Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? Mar 108–111
Fawcett J see Zajecka J
Fawcett RG. Cerebral infarct presenting as mania [letter]. Aug 352–353
Feder R. Bradycardia and syncope induced by fluoxetine [letter with reply]. Mar 139
Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. Apr 163–164
Feerick J see Liebowitz MR
Feighner JP, Gardner EA, Johnston JA, Batey SR, Khayrallah MA, Ascher JA, Lineberry CG. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. Aug 329–335
Feighner JP see Boyer WF; Johnston JA
Feinberg SS see Opler LA
Fesler FA. Valproate in combat-related posttraumatic stress disorder. Sept 361–364
Fishbain DA. Personality disorder diagnoses in old age [letter with reply]. Nov 477–478
Flowers E see Salzman C
Flynn TM see Pollard CA
Fogel BS, Westlake R. Reply to Fishbain DA: Personality disorder diagnoses in old age [letter]. Nov 477–478
Forbes RA see Arana GW
Ford SM see Davidson JRT
Förstl H, Burns A, Jacoby R, Levy R. Neuroanatomical correlates of clinical misidentification and misperception in senile dementia of the Alzheimer type. June 268–271
Frances AJ see Kocsis JH
Franco S see Cleghorn JM
Frankenburg FR see McElroy SL; Strakowski SM
Friedman EH. Anxiety disorders during acute bereavement [letter with reply]. May 241
Friedman EH. Brain abnormalities in schizophrenia [letter with reply]. Jan 43
Friedman EH. Clomipramine treatment of trichotillomania [letter]. Nov 478–479
Friedman EH. Fluoxetine-induced bradycardia [letter with reply]. Nov 477
Friedman EH. Role of the right hemisphere in fluoxetine-induced bradycardia and syncope [letter]. Mar 138–139
Friedman EH. Speech hesitation pauses as markers for mood disorder in stroke patients [letter with reply]? Mar 140
Friedman EH. Speech pauses and diagnosis [letter]. Apr 181–182
Friedman LJ see Perilstein RD
Friedman R see Krupp LB
Frontera MA see Spier SA
Fuller RW. Role of serotonin in therapy of depression and related disorders. May suppl 52–57
Fuselier CC see Goad DL
Gainsley B see Gwirtsman HE
Garbutt JC see Golden RN
Gardner EA see Feighner JP
Gaumer RH see Wolf TM
Gelenberg AJ. Auld Lang Syne [editorial]. Feb 54–55
Gelenberg AJ. Holiday greetings [editorial]. Dec 489–490
Gelenberg AJ. Introduction. Clinician's challenge: strategies for treatment of depression in the 1990s. June suppl 3
Gelenberg AJ. Psychiatry in the 1990s [editorial]. May 205–207
Gelenberg AJ. Psychiatry, psychology, and psychopharmacology [editorial]. Jan 3
Gelenberg AJ. Summary. Clinician's challenge: strategies for treatment of depression in the 1990s. June suppl 68–69. Correction, July 319
Gerard M-J see Rouillon F
Giannini AJ, Slaby AE, Robb TO. De Clérambault's syndrome in sexually experienced women. Feb 84–86
Giardina EGV see Roose SP
Gilboa R see Buff DD
Gill K see Amit Z
Gilmore JH see Golden RN
Gitow A see Liebowitz MR
Glassman AH see Roose SP
Glassman R see Salzman C
Gleghorn A see Harris MJ
Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer's patients with behavior problems. Aug 342–345
Gold DD Jr. Review of Asaad G: *Hallucinations in Clinical Psychiatry: A Guide for Mental Health Professionals*. Nov 482
Gold DD Jr. Review of Hall P, Brockington IF (eds): *The Closure of Mental Hospitals*. Dec 517
Gold DD Jr. Review of Hillard JR (ed): *Manual of Clinical Emergency Psychiatry*. Jan 45–46
Gold DD Jr. Review of Isaac RJ, Armat VC: *Madness in the Streets: How Psychiatry and the Law Abandoned the Mentally Ill*. Apr 190–191
Goldberg RL see Silver PA
Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. June 261–262
Golden RN, Gilmore JH, Corrigan MHN, Ekstrom RD, Knight BT, Garbutt JC. Serotonin, suicide, and aggression: clinical studies. Dec suppl 61–69
Gosnell BA see Krahn DD
Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. Sept suppl 4–10
Greenblatt DJ. Introduction. Benzodiazepine hypnotics: the interface of basic and clinical science. Sept suppl 3
Greenwald E see Pitman RK
Greist JH, Jefferson JW. Reply to Lee S: Clomi-

pramine in obsessive compulsive disorder [letter]. Apr 183–185
Grieger TA, Clayton AH. Reply to Cocores JA: Ganser's syndrome clarification [letter]. Apr 185–186
Guterman A see Sevush S
Guy C see Zajecka J
Guze BH see Gwirtsman HE
Gwirtsman HE, Guze BH, Yager J, Gainsley B. Reply to Lee S: Fluoxetine in anorexia nervosa [letter]. May 240–241
Halbreich U, Rojansky N, Bakhai Y, Wang K. Menstrual irregularities associated with bupropion treatment. Jan 15–16
Harris GJ see Hoehn-Saric R
Harris MJ, Jeste DV, Gleghorn A, Sewell DD. New-onset psychosis in HIV-infected patients. Sept 369–376
Hart RH. Review of McCully RS: *The Enigma of Symbols in Fairy Tales.* Dec 516–517
Hart RH. Review of Nathanson DL (ed): *The Many Faces of Shame.* July 321
Heckmann RC. Prescribing privileges for psychologists [letters with replies]. July 315–316
Heiman MF. Review of Osgood NJ, Brant BA, Lipman A (eds): *Suicide Among the Elderly in Long-Term Care Facilities.* Oct 435–436
Heimberg RG, Barlow DH. New developments in cognitive-behavioral therapy for social phobia. Nov suppl 21–30
Henigan MH. Review of Stark KD; Elliott SN, Witt JC (eds): *Childhood Depression: School-Based Intervention.* July 320
Herman JB see Tesar GE
Hermesh H see Aizenberg D
Hernandez L, Parada M, Baptista T, Schwartz D, West HL, Mark GP, Hoebel BG. Hypothalamic serotonin in treatments for feeding disorders and depression as studied by brain microdialysis. Dec suppl 32–40
Herold M see Kinzl J
Herzog DB. Introduction. Recent advances in bulimia nervosa. Oct suppl 3
Herzog DB, Keller MB, Lavori PW, Sacks NR. Course and outcome of bulimia nervosa. Oct suppl 4–8
Hickie I see Cullen M
Higgins GA see Sellers EM
Hilbert JM, Battista D. Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics. Sept suppl 21–26
Hill JL see Vitiello B
Hill PB. Review of Hale MS (ed): *Methods in Teaching Consultation-Liaison Psychiatry.* Apr 191–192
Hill PB. Review of Stotland NL, Garrick TR: *Manual of Psychiatric Consultation.* Mar 143
Himes JA see Comings DE
Hindmarch I. Residual effects of hypnotics: an update. July suppl 14–15
Hirshfeld DR see Rosenbaum JF
Hishikawa Y. Appropriate use of benzodiazepines in insomnia: clinical update. July suppl 10–13
Hishikawa Y, Schatzberg AF. Introduction. Anxiety and insomnia: current trends in research and therapeutics. July suppl 3–4
Hishikawa Y, Schatzberg AF. Summary. Anxiety and insomnia: current trends in research and therapeutics. July suppl 27
Hoch CC see Pasternak RE
Hoebel BG see Hernandez L
Hoehn-Saric R, Harris GJ, Pearlson GD, Cox CS, Machlin SR, Camargo EE. Fluoxetine-induced frontal lobe syndrome in an obsessive compulsive patient. Mar 131–133
Hollander E, Mullen L, DeCaria CM, Skodol A, Schneier FR, Liebowitz MR, Klein DF. Obsessive compulsive disorder, depression, and fluoxetine. Oct 418–422
Hollander E see Fallon BA; Liebowitz MR; Stein DJ
Hom J see Weiner MF
Houck PR see Pasternak RE
Hsu LKG see Kaye WH
Hudson JI see Strakowski SM
Huessy HR. Review of Bloomingdale LM, Swanson J (eds): *Attention Deficit Disorder.* Feb 92
Hughes DH. Review of Nemiroff RA, Colarusso CA (eds): *New Dimensions in Adult Development.* Apr 191
Hunt JI see Simpson GM
Hunt MAE see Wamsley JK
Hurwitz S see Rosenberg PB
Hutto BR see Malcolm R
Hyer LA, Summers MN. Reply to Alvarez WA, Shipko S: Alexithymia and posttraumatic stress disorder [letter]. July 317–318
Ibe IO see Pollard CA
Isaac G. Bipolar disorder in prepubertal children in a special educational setting: is it rare? Apr 165–168
Itil TM see Fabre LF
Jacobs BL. Serotonin and behavior: emphasis on motor control. Dec suppl 17–23
Jacobs S. Reply to Friedman EH: Anxiety disorders during acute bereavement [letter]. May 241
Jacobsen FM. Possible augmentation of antidepressant response by buspirone. May 217–220
Jacoby R see Förstl H
Javitch JA see Fallon BA
Jefferson JW see Greist JH
Jeffriess H see Zajecka J
Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. Jan 13–14
Jeste DV see Harris MJ
Joffe RT see Levitt AJ
Johnson RP see Wells BG
Johnston JA, Lineberry CG, Ascher JA, Davidson J, Khayrallah MA, Feighner JP, Stark P. 102-center prospective study of seizure in association with bupropion. Nov 450–456
Johnston JA see Feighner JP
Jonas AG. Prescribing privileges for psychologists [letter with reply]. July 313–317
Joseph AB, O'Leary DH. Reply to Friedman EH: Brain abnormalities in schizophrenia [letter]. Jan 43
Josephson SC see Stein DJ
Judd FK see Burrows GD
Kaffeman M see Scharf MB
Kafka MP. Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. Feb 60–65
Kaplan RD see Cleghorn JM
Karagianis JL. Effects of placebo washout and dose in a comparison of sertraline and amitriptyline [letter with reply]. Sept 386
Karp L see Aizenberg D
Kasparek C. Prescribing privileges for psychologists [letter with reply]. July 313–317
Kathol RG see Miller DD
Katz MR. Raised serum levels of desipramine with the antiarrhythmic propafenone [letter]. Oct 432–433
Kaye WH, Weltzin TE. Neurochemistry of bulimia nervosa. Oct suppl 21–28
Kaye WH, Weltzin TE. Serotonin activity in anorexia and bulimia nervosa: relationship to the modulation of feeding and mood. Dec suppl 41–48
Kaye WH, Weltzin TE, Hsu LKG, Bulik CM. Open trial of fluoxetine in patients with anorexia nervosa. Nov 464–471
Keck PE Jr, Carter WP, Nierenberg AA, Cooper TB, Potter WZ, Rothschild AJ. Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels. June 250–254
Keck PE Jr see McElroy SL; Pope HG Jr; Strakowski SM
Keller MB see Herzog DB
Kellner CH. Labetalol and ECT [letter with reply]. Sept 386–387
Kennedy SH see Goldbloom DS; Levitt AJ
Kerr JZ. Review of Lewis M, Volkmar F: *Clinical Aspects of Child and Adolescent Development, 3rd ed.* May 244
Khanna R, Chatterjee S. Polyarthritis: an unusual side effect of lithium [letter]. Jan 43–44
Khanna R, Nizamie SH, Das A. Electrical trauma, nonictal EEG changes, and mania: a case report [letter]. June 280
Khayrallah MA see Feighner JP; Johnston JA
Kim SW, Dysken MW. Potential antidopaminergic effects of serotonin reuptake inhibitors [letter]. Jan 42
King P. Review of Feigelman W: *Treating Teenage Drug Abuse in a Day Care Setting.* Jan 47
King P. Review of Jaffe SL: *Adolescent Chemical Dependency Recovery.* Mar 142
King P. Review of Kaufman E: *Help at Last: A Complete Guide to Coping With Chemically Dependent Men.* Oct 435
Kinzl J, Biebl W, Herold M. Hyperamylasemia and salivary gland enlargements in patients with eating disorders [letter]. Mar 139–140
Kirtane SS see Buff DD
Kitchen AD see Pollard CA
Klein DF. Abstract presentation. The pathophysiology of panic anxiety. Feb suppl 10–11
Klein DF see Hollander E
Klerman GL. Conclusions. Panic disorder: strategies for long-term treatment. Feb suppl 33
Klerman GL. Introduction. Panic disorder: strategies for long-term treatment. Feb suppl 3–5
Klerman GL see Deltito JA
Knight BT see Golden RN
Knos G, Stoudemire A. Reply to Kellner CH: Labetalol and ECT [letter]. Sept 386–388
Knos G, Stoudemire A. Reply to Silver PA: Labetalol and ECT [letter]. Sept 387–388
Knott DH see Wells BG
Kocsis JH, Sutton BM, Frances AJ. Long-term follow-up of chronic depression treated with imipramine. Feb 56–59
Kontras SB. Review of Eiser C: *Chronic Childhood Disease: An Introduction to Psychological Theory and Research.* July 320
Krahn DD, Nairn K, Gosnell BA, Drewnowski A. Stealing in eating disordered patients. Mar 112–115
Krall R see Scharf MB
Krishnan KRR see Davidson JRT; Potts NLS
Krojanker DN see Pollard CA
Krupp LB, Mendelson WB, Friedman R. Overview of chronic fatigue syndrome. Oct 403–410
Kuhne AA. Review of Luborsky L, Crits-

Christoph P: *Understanding Transference: The Core Conflictual Relationship Theme Method.* Mar 141–142
Kupfer DJ. Lessons to be learned from long-term treatment of affective disorders: potential utility in panic disorder. Feb suppl 12–16
Kupfer DJ. Long-term treatment of depression. May suppl 28–34
Kupfer DJ. Reply to Shrader SA: Defining *recovery* and *remission* [letter]. Oct 433–434
Lam RW, Buchanan A, Clark CM, Remick RA. Ultraviolet versus non-ultraviolet light therapy for seasonal affective disorder. May 213–216
Landy DA. Prescribing privileges for psychologists [letters with replies]. July 311–316
Larocca FEF. Review of Woodside DB, Shekter-Wolfson L (eds): *Family Approaches in Treatment of Eating Disorders.* Oct 436
Lavori PW see Herzog DB
Lazarus A. Brachial plexopathy complicating neuroleptic malignant syndrome [letter]. May 239–240
LeBon O see Verbanck PMP
Lee HS see Alphs LD
Lee S. Clomipramine in obsessive compulsive disorder [letter with reply]. Apr 183–184
Lee S. Fluoxetine in anorexia nervosa [letter with reply]. May 240–241
Lee S. MAOI and monosodium glutamate interaction [letter]. Jan 43
Lelliott P see O'Sullivan G
Lellouch J see Pariente PhD
Lepine JD see Pariente PhD
Levine SB. Review of Blanchard R, Steiner BW (eds): *Clinical Management of Gender Identity Disorders in Children and Adults.* June 283
Levine SB. Review of Stotland NL (ed): *Psychiatric Aspects of Reproductive Technologies.* Sept 390
Levine SH. Reply to Dommisse J: Pseudotumor cerebri associated with lithium therapy in two patients [letter]. May 239
Levitt AJ, Joffe RT, Kennedy SH. Bright light augmentation in antidepressant nonresponders. Aug 336–337
Levy R see Förstl H
Lieberman JA see Szymanski S
Liebowitz MR, Schneier FR, Hollander E, Welkowitz LA, Saoud JB, Feerick J, Campeas R, Fallon BA, Street L, Gitow A. Treatment of social phobia with drugs other than benzodiazepines. Nov suppl 10–15
Liebowitz MR see Fallon BA; Hollander E
Liem P see Goad DL
Lineberry CG see Feighner JP; Johnston JA
Links PS. Review of Plakun EM (ed): *New Perspectives on Narcissism.* Apr 189–190
Lipper S see Perilstein RD
Locke CA see Rothschild AJ
Longpre RE see Pitman RK
Lorefice LS. Fluoxetine treatment of a fetish [letter]. Jan 41
Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drugs. Dec suppl 24–31
Lukas SE see Stoll AL
Lukasik V see Fallon BA
Luxenberg M see Tollefson GD
Lydiard RB. Coexisting depression and anxiety: special diagnostic and treatment issues. June suppl 48–54
Lydiard RB see Brady KT
Machlin SR see Hoehn-Saric R
Mackenzie TB see Christenson GA
Macklin ML see Pitman RK
Malcolm R, Hutto BR, Phillips JD, Ballenger JC. Pergolide mesylate treatment of cocaine withdrawal. Jan 39–40
Malcolm R see Brady KT
Mark GP see Hernandez L
Marken PA see Wells BG
Markowitz JC. Fluoxetine and dreaming [letter]. Oct 432
Marks I see O'Sullivan G
Masiar S see Szymanski S
Masiar SJ. ECT response and blood pressure reduction [letter with reply]. Apr 183
Mayleben DW see Scharf MB
Mayor J, Rice J, Bielski RJ. Environmental influences on the onset of winter depression [letter]. Nov 480
Mayor J see Rice J
Mazurek M see Rosebush PI
Mazurek MF see Rosebush PI
McCance-Katz EF. New onset Raynaud's Phenomenon in a schizophrenic patient [letter]. Feb 89–90
McCormack JR see Goad DL
McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, Aizley HG, O'Brien S. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. Oct 411–414
McElroy SL see Pope HG Jr
McLeer SV see Vitiello B
Meltzer HY. Beyond serotonin. May suppl 58–62
Meltzer HY. Introduction. Multiple roles and actions of serotonin systems. Dec suppl 3
Meltzer HY. Summary. The significance of serotonin for neuropsychiatric disorders. Dec suppl 70–72
Mendels J. Criteria for selection of appropriate benzodiazepine hypnotic therapy. Sept suppl 42–46
Mendelson WB see Krupp LB
Menza MA. Lorazepam and catatonia [letter with reply]. Apr 186–187
Metz A. Prescribing privileges for psychologists [letter with reply]. July 312–317
Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. Jan 23–25
Miller DD, Sharafuddin MJA, Kathol RG. Case of clozapine-induced neuroleptic malignant syndrome. Mar 99–101
Miller HD see Rouillon F
Miller MG see Tohen M
Milofsky JE see Ellison JM
Mitchell JE, Specker SM, de Zwaan M. Comorbidity and medical complications of bulimia nervosa. Oct suppl 13–20
Mitchell JE see Christenson GA
Mitchell P see Cullen M
Miyawaki E see Salzman C
Monteiro W see O'Sullivan G
Moral L see de Leon J
Morewitz J see Ware JC
Morse EV see Wolf TM
Mullen L see Hollander E
Mumtaz SS. Review of Etezady MH (ed): *The Neurotic Child and Adolescent.* May 243–244
Nairn K see Krahn DD
Name Withheld Upon Request. Clobazam and panic disorder [letter]. Jan 44
Nasdahl CS see Wells BG
Nasrallah HA. Review of Hauser P (ed): *Brain Imaging in Affective Disorders.* Dec 516
Nemeroff CB. Augmentation regimens for depression. May suppl 21–27
Nierenberg AA. Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists. Sept 383–385
Nierenberg AA, Cole JO. Antidepressant adverse drug reactions. June suppl 40–47
Nierenberg AA see Keck PE Jr
Nizamie SH see Khanna R
Norman TR see Burrows GD
North CS. Review of Johnson AB: *Out of Bedlam: The Truth About Deinstitutionalization.* Apr 189
Noshirvani H see O'Sullivan G
O'Brien PD. Thromboembolism complicating psychiatric stupor [letter]. Mar 137–138
O'Brien S see McElroy SL
Ochs R see Scharf MB
Okada F. Is the tendency to weep one of the most useful indicators for depressed mood? [letter]. Aug 351–352
O'Leary DH see Joseph A
Olsen KM see Goad DL
Opler LA, Feinberg SS. Reply to Phillips KA: Pimozide in clinical psychiatry [letter]. Dec 514–515
Opler LA, Feinberg SS. Role of pimozide in clinical psychiatry: a review. May 221–233
Orvaschel H see Apter A
O'Sullivan G, Noshirvani H, Marks I, Monteiro W, Lelliott P. Six-year follow-up after exposure and clomipramine therapy for obsessive compulsive disorder. Apr 150–155
Otto M see Tesar GE
Panarites HC see Deltito JA
Parada M see Hernandez L
Pariente PhD, Lepine JD, Lellouch J. Lifetime history of panic attacks and epilepsy: an association from a general population survey [letter]. Feb 88–89
Parker G see Cullen M
Parks A see Ratey J
Pasternak RE, Reynolds CF III, Schlernitzauer M, Hoch CC, Buysse DJ, Houck PR, Perel JM. Acute open-trial nortriptyline therapy of bereavement-related depression in late life. July 307–310
Pataki CS. Review of Menkes JH: *Textbook of Child Neurology, 4th ed.* Nov 483
Pearlson GD see Hoehn-Saric R
Pearlstein TB see Stone AB
Peet M. Supersensitivity psychosis [letter with reply]. Feb 90
Perel JM see Pasternak RE
Perilstein RD, Lipper S, Friedman LJ. Three cases of paraphilias responsive to fluoxetine treatment. Apr 169–170
Peterson GN. Strategies for fluoxetine-MAOI combination therapy [letter with reply]. Feb 87–88
Phillips JD see Malcolm R
Phillips KA. Pimozide in clinical psychiatry [letter with reply]. Dec 514–515
Picou D see Szymanski S
Pies RW. "Deep structure" of clinical medicine and prescribing privileges for psychologists [special article]. Jan 4–8
Pies RW. Reply to Dawson G; Landy DA: Prescribing privileges for psychologists [letters]. July 311–312
Pies RW. Reply to Kasparek C; Jonas AG; Clark DB; Smith JM; Heckmann RC: Prescribing privileges for psychologists [letters]. July 313–316
Pies RW. Reply to Metz A: Prescribing privileges

for psychologists [letter]. July 312–313
Pies RW. Reply to Sovner R: Nurse clinical-specialists as nonphysician prescribers [letter]. Dec 515
Pitman RK, Altman B, Greenwald E, Longpre RE, Macklin ML, Poiré RE, Steketee GS. Psychiatric complications during flooding therapy for posttraumatic stress disorder. Jan 17–20
Pohl R see Balon R
Poiré RE see Pitman RK
Pollack MH, Rosenbaum JF. Fluoxetine treatment of cocaine abuse in heroin addicts. Jan 31–33
Pollack MH see Tesar GE
Pollard CA, Ibe IO, Krojanker DN, Kitchen AD, Bronson SS, Flynn TM. Clomipramine treatment of trichotillomania: a follow-up report on four cases. Mar 128–130
Pope HG Jr, Aizley HG, Keck PE Jr, McElroy SL. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. May 208–212
Pope HG Jr see McElroy SL
Popkin MK see Christenson GA
Potter WZ see Keck PE Jr
Potts NLS, Davidson JRT, Krishnan KRR, Doraiswamy PM, Ritchie JC. Levels of urinary free cortisol in social phobia. Nov suppl 41–42
Potts NLS see Davidson JRT
Powers PS see Anderson ES
Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. June suppl 23–33. Correction, Aug 353
Pultz JA see Beasley CM Jr
Puzzuoli G see Rickels K
Pyle RL see Christenson GA
Raj BA. Review of Zal HM: *Panic Disorder: The Great Pretender*. May 242
Ratey J, Sovner R, Parks A, Rogentine K. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple-baseline, placebo lead-in study. Apr 159–162
Realmuto GM see Christenson GA
Reimherr FW. Reply to Karagianis JL: Effects of placebo washout and dose in a comparison of sertraline and amitriptyline [letter]. Sept 386
Remick RA see Lam RW
Reynolds CF III see Pasternak RE
Rice J, Mayor J, Bielski RJ. Phototherapeutic response variability in seasonal affective disorder [letter]. Aug 349
Rice J see Mayor J
Rice SN. Review of Fleischman PR: *The Healing Spirit: Explorations in Religion and Psychotherapy*. Aug 355
Richelson E. Biological basis of depression and therapeutic relevance. June suppl 4–10. Correction, Aug 353
Richichi EA see Davidson JRT
Rickels K, Amsterdam JD, Clary C, Puzzuoli G, Schweizer E. Buspirone in major depression: a controlled study. Jan 34–38
Ritchie JC see Potts NLS
Robb TO see Giannini AJ
Robinson RG. Reply to Friedman: Speech hesitation pauses as markers for mood disorder in stroke patients [letter]? Mar 140
Roehrs TA see Roth T
Rogentine K see Ratey J
Rojansky N see Halbreich U
Romach MK see Sellers EM
Rood L see Salzman C
Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV. Is doxepin a safer tricyclic for the heart? Aug 338–341
Roose SP, Dalack GW, Woodring S. Death, depression, and heart disease. June suppl 34–39
Rosebush PI, Mazurek M. Bromocriptine and neuroleptic malignant syndrome [letter]. Jan 41–42
Rosebush PI, Mazurek MF. Reply to Menza MA: Lorazepam and catatonia [letter]. Apr 186–188
Rosenbaum JF. Closing remarks. The changing horizon in the treatment of depression and related disorders. May suppl 63–64
Rosenbaum JF. Introduction. The changing horizon in the treatment of depression and related disorders. May suppl 3
Rosenbaum JF, Biederman J, Hirshfeld DR, Bolduc EA, Chaloff J. Behavioral inhibition in children: a possible precursor to panic disorder or social phobia. Nov suppl 5–9
Rosenbaum JF see Fava M; Pollack MH; Tesar GE
Rosenberg PB, Ahmed I, Hurwitz S. Methylphenidate in depressed medically ill patients. June 263–267
Rosenthal RH. Review of Franks CM, Wilson GT, Kendall PC, Foreyt JP: *Review of Behavior Therapy: Theory and Practice, vol. 12*. May 242–243
Ross J. Social phobia: the Anxiety Disorders Association of America helps raise the veil of ignorance. Nov suppl 43–47
Roth T, Roehrs TA. Review of the safety profiles of benzodiazepine hypnotics. Sept suppl 38–41
Rothschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. Dec 491–493
Rothschild AJ see Keck PE Jr
Rouillon F, Serrurier D, Miller HD, Gerard M-J. Prophylactic efficacy of maprotiline on unipolar depression relapse. Oct 423–431
Rummans TA see Bassingthwaighte ME
Sabelli HC. Rapid treatment of depression with selegiline-phenylalanine combination [letter]. Mar 137. Correction, May 241
Sachs GS see Tesar GE
Sacks NR see Herzog DB
Sadik C see Fallon BA
St. John R. Review of Bergmann MS, Hartman FR (eds): *The Evolution of Psychoanalytic Technique*. June 283–284
St. John R. Review of Esman AH (ed): *Essential Papers on Transference*. Sept 389
Salcedo MS see Vaz FJ
Salzman C, Soloman D, Miyawaki E, Glassman R, Rood L, Flowers E, Thayer S. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. Apr 177–180
Samuels A. More on the effects of monosodium glutamate [letter with reply]. Aug 350–351
Saoud JB see Fallon BA; Liebowitz MR
Satel SL, Seibyl JP, Charney DS. Prolonged cocaine psychosis implies underlying major psychopathology [letter]. Aug 349–350
Sayler ME see Beasley CM Jr
Schaff M see Zajecka J
Scharf MB, Mayleben DW, Kaffeman M, Krall R, Ochs R. Dose response effects of zolpidem in normal geriatric subjects. Feb 77–83
Scharf MB see Fabre LF
Schatzberg AF. Anxiety and adjustment disorder: a treatment approach, 1990 Nov suppl 20–24. Correction, Mar 140
Schatzberg AF. Dosing strategies for antidepressant agents. May suppl 14–20
Schatzberg AF. Overview of anxiety disorders: prevalence, biology, course, and treatment. July suppl 5–9
Schatzberg AF, Ballenger JC. Decisions for the clinician in the treatment of panic disorder: when to treat, which treatment to use, and how long to treat. Feb suppl 26–31
Schatzberg AF see Hishikawa Y
Schlernitzauer M see Pasternak RE
Schneier FR see Hollander E; Liebowitz MR
Schou M. Reply to Shafey MH: Lithium use and pregnancy [letter]. June 279
Schuster JM. Review of Lindsay J, MacDonald A, Starke I: *Delirium in the Elderly*. Dec 517
Schwartz D see Hernandez L
Schweizer E see Rickels K
Scott AM. Review of Cohen NL (ed): *Psychiatry Takes to the Streets: Outreach and Crisis Intervention for the Mentally Ill*. Aug 354–355
Seibyl JP see Satel SL
Sellers EM, Higgins GA, Tomkins DM, Romach MK, Toneatto T. Opportunities for treatment of psychoactive substance use disorders with serotonergic medications. Dec suppl 49–54
Serrurier D see Rouillon F
Settle EC Jr. Tinnitus related to bupropion treatment [letter]. Aug 352
Sevush S, Guterman A, Villalon AV. Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type. July 300–303
Sewell DD see Harris MJ
Shafey MH. Lithium use and pregnancy [letter with reply]. June 279
Shaktman D. Tourette's syndrome in the developmentally disabled [letter with reply]. June 279
Sharafuddin MJA see Miller DD
Sheeley WF. Malingering [letter with reply]. June 281–282
Shipko S see Alvarez WA
Shrader SA. Defining *recovery* and *remission* [letter with reply]. Oct 433–434
Silver PA, Goldberg RL. Labetalol and ECT [letter with reply]. Sept 387
Simon PM see Wolf TM
Simpson GM, Singh H, Hunt JI, Vitiello B. Reply to Peet M: Supersensitivity psychosis [letter]. Feb 90
Singh H see Simpson GM
Skodol A see Hollander E
Slaby AE see Giannini AJ
Small GW. Recognition and treatment of depression in the elderly. June suppl 11–22
Smith BR see Amit Z
Smith JM. Prescribing privileges for psychologists [letter with reply]. July 314–316
Smith RD see Davidson JRT
Soloman D see Salzman C
Soltys SM. Review of Barkley RA (ed): *Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*. Oct 436
Sovner R, Bailey KP. Nurse clinical-specialists as nonphysician prescribers [letter with reply]. Dec 515
Sovner R see Ratey J
Specker SM see Mitchell JE
Spier SA, Frontera MA. Unexpected deaths in de-

pressed medical inpatients treated with fluoxetine. Sept 377–382
Spier SA see Tesar GE
Spivak B see Apter A
Stanley MA, Bowers TC, Swann AC, Taylor DJ. Treatment of trichotillomania with fluoxetine [letter]. June 282
Stark P see Johnston JA
Stein DJ, Bruun RD, Josephson SC, Hollander E. Obsessional severity in Tourette's syndrome [letter]. Sept 388
Steketee GS see Pitman RK
Stokes PE. Changing horizon in the treatment of depression: scientific/clinical publication overview. May suppl 35–43
Stoll AL, Cole JO, Lukas SE. Case of mania as a result of fluoxetine-marijuana interaction [letter]. June 280–281
Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. July 290–293
Stoudemire A see Knos G
Strakowski SM, Hudson JI, Keck PE Jr, Wilson DR, Frankenburg FR, Alpert JE
Strassman RJ. Review of Frances RJ, Miller SI (eds): *Clinical Textbook of Addictive Disorders.* Oct 435
Street L see Liebowitz MR
Strober M. Family-genetic studies of eating disorders. Oct suppl 9–12
Summers MN see Hyer LA
Surawicz FG. Review of Everett CA (ed): *Children of Divorce: Developmental and Clinical Issues.* July 320–321
Surawicz FG. Review of Fogel BS, Furino A, Gottlieb GL (eds): *Mental Health Policy for Older Americans: Protecting Minds at Risk.* Feb 91–92
Surawicz FG. Review of Notman MT, Nadelson CC (eds): *Women and Men: New Perspectives on Gender Differences.* Dec 516
Sutton BM see Kocsis JH
Svetlik D see Weiner MF
Swann AC see Stanley MA
Swartz CM. Reply to Masiar SJ: ECT response and blood pressure reduction [letter]. Apr 183
Szechtman B see Cleghorn JM
Szechtman H see Cleghorn JM
Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. Case report of cimetidine-induced clozapine toxicity. Jan 21–22
Tanay E. Review of Kates N, Greiff BS, Hagen DQ: *The Psychosocial Impact of Job Loss.* Jan 45
Tanay E. Review of Young RA, Borgen WA (eds): *Methodological Approaches to the Study of Career.* May 242
Tancer ME see Uhde TW
Taylor DJ see Stanley MA
Tesar GE, Rosenbaum JF, Pollack MH, Otto M, Sachs GS, Herman JB, Cohen LS, Spier SA. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. Feb 69–76
Teschke GC, Tohen M. Four cases of obstructive sleep apnea associated with treatment-resistant mania. Apr 156–158
Teschke GC see Strakowski SM
Thayer S see Salzman C
Tintner R see Weiner MF
Tohen M, Castillo J, Cole JO, Miller MG, de los Heros R, Farrer RJ. Thrombocytopenia associated with carbamazepine: a case series. Dec 496–498
Tohen M see Strakowski SM
Tollefson GD. Antidepressant treatment and side effect considerations. May suppl 4–13
Tollefson GD, Luxenberg M, Valentine R, Dunsmore G, Tollefson SL. Open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. Dec 502–508
Tollefson SL see Tollefson GD
Tomkins DM see Sellers EM
Toneatto T see Sellers EM
Tyano S see Apter A
Uhde TW, Tancer ME, Black B, Brown TM. Phenomenology and neurobiology of social phobia: comparison with panic disorder. Nov suppl 31–40
Uhlenhuth EH see Balter MB
Usher RW, Beasley CM Jr, Bosomworth JC. Efficacy and safety of morning versus evening fluoxetine administration. Mar 134–136
Valentine R see Tollefson GD
Vaz FJ, Salcedo MS. Fluoxetine treatment of depressive symptoms in acute intermittent porphyria [letter]. Mar 138
Verbanck PMP, LeBon O. Changing psychiatric symptoms in a patient with vitamin B_{12} deficiency [letter]. Apr 182–183
Villalon AV see Sevush S
Vitiello B, Hill JL, Elia J, Cunningham E, McLeer SV, Behar D. P.R.N. medications in child psychiatric patients: a pilot placebo-controlled study. Dec 499–501
Vitiello B see Simpson GM
Walker P. Review of Committee on Medical Education of the Group for the Advancement of Psychiatry: *A Casebook in Psychiatric Ethics.* May 243
Walsh BT. Psychopharmacologic treatment of bulimia nervosa. Oct suppl 34–38
Walsh BT see Fallon BA; Roose SP
Wamsley JK, Hunt MAE. Relative affinity of quazepam for type-1 benzodiazepine receptors in brain. Sept suppl 15–20
Wang K see Halbreich U
Ward NG, Davidson RC. Gastric absorption of nifedipine [letter]. Apr 188
Ware JC, Morewitz J. Diagnosis and treatment of insomnia and depression. June suppl 55–61
Weiner MF, Bruhn M, Svetlik D, Tintner R, Hom J. Experiences with depression in a dementia clinic. May 234–238
Weissman MM. Panic disorder: impact on quality of life. Feb suppl 6–8
Weizman A see Aizenberg D; Apter A
Welkowitz LA see Liebowitz MR
Wells BG, Cold JA, Marken PA, Brown CS, Chu C-C, Johnson RP, Nasdahl CS, Ayubi MA, Knott DH, Arheart KL. Placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. June 255–260
Weltzin TE see Kaye WH
West HL see Hernandez L
Westlake R see Fogel BS
Whitaker-Azmitia PM see Azmitia EC
Wilhelm K see Cullen M
Williams MH see Wolf TM
Wilson DR see Strakowski SM
Wilson W see Davidson JRT
Wise TN. Review of Kammerer WS, Gross RJ (eds): *Medical Consultation: The Internist on Surgical, Obstetric, and Psychiatric Services.* Sept 389
Wise TN. Review of Sandler M, Collins GM (eds): *Migraine: A Spectrum of Ideas.* Mar 141
Wolf TM, Balson PM, Morse EV, Simon PM, Gaumer RH, Dralle PW, Williams MH. Relationship of coping style to affective state and perceived social support in asymptomatic and symptomatic HIV-infected persons: implications for clinical management. Apr 171–173
Woodring S see Roose SP
Yager J see Gwirtsman HE
Yeomans F. Review of Shapiro D: *Psychotherapy of Neurotic Character.* Jan 46
Yeragani VK see Balon R
Young A see DasGupta K
Yudofsky SC. Reply to Sheeley SC: Malingering [letter]. June 281–282
Zajecka J, Fawcett J. Susceptibility to spontaneous MAOI hypertensive episodes [letter]. Dec 513–514
Zajecka J, Fawcett J, Schaff M, Jeffriess H, Guy C. Role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. Feb 66–68
Zemishlany Z see Aizenberg D